These innovative molecules represent a significant advancement in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://fannieclma933916.fitnell.com/79949390/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide